KPG 612
Alternative Names: KPG-612Latest Information Update: 16 Mar 2023
At a glance
- Originator Kangpu Biopharmaceuticals
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Behcet's syndrome; Plaque psoriasis; Psoriatic arthritis
Most Recent Events
- 16 Mar 2023 Discontinued - Preclinical for Behcet's syndrome in China (unspecified route) (Kangpu Biopharmaceuticals pipeline, March 2023)
- 16 Mar 2023 Discontinued - Preclinical for Plaque psoriasis in China (unspecified route) (Kangpu Biopharmaceuticals pipeline, March 2023)
- 16 Mar 2023 Discontinued - Preclinical for Psoriatic arthritis in China (unspecified route) (Kangpu Biopharmaceuticals pipeline, March 2023)